Regulation of Ferroptosis by Transcription Factor E2F1 and RB

Area of Science:

• Cell Biology
• Cancer Research
• Molecular Biology

Background:

• Tumor suppressor RB protein interacts with E2F transcription factors to control cell cycle progression.
• Cyclin-dependent kinases (CDKs) regulate RB/E2F interactions via RB phosphorylation.
• Previous research indicated that CDK2, RB, and E2F proteins inhibit ferroptosis.

Purpose of the Study:

• To investigate the role of CDK2 in suppressing ferroptosis through RB phosphorylation.
• To elucidate the regulatory function of E2F1 on ferroptosis-associated genes.
• To examine the compensatory role of E2F3 in response to E2F1 depletion.

Main Methods:

• Overexpression of wild-type RB (WT-RB) or a CDK-resistant RB mutant (RBΔCDK) with CDK2/cyclinE.
• Analysis of ferroptosis markers and cell death.
• Gene expression analysis of ferroptosis regulators (e.g., ALOX5, MYC, SLC7A11, ATF4, GPX4).
• E2F1 knockdown and assessment of E2F3 compensatory effects in osteosarcoma cell lines.

Main Results:

• CDK2 suppresses ferroptosis, mediated by RB phosphorylation.
• E2F1 demonstrates a net inhibitory effect on ferroptosis by regulating pro- and anti-ferroptotic proteins.
• E2F3 exhibits cell-type-dependent compensation for E2F1 loss, maintaining ferroptosis gene expression levels in osteosarcoma cells.

Conclusions:

• Cell cycle regulatory proteins, including CDK2, RB, and E2F family members, play a crucial role in protecting cancer cells from ferroptosis.
• Targeting these cell cycle regulators could offer novel therapeutic strategies against ferroptosis-vulnerable cancers.